Antibody-mediated rejection criteria - An addition to the Banff '97 classification of renal allograft rejection

Lorraine C. Racusen, Robert B. Colvin, Kim Solez, Michael J. Mihatsch, Philip F. Halloran, Patricia M. Campbell, Michael J. Cecka, Jean Pierre Cosyns, Anthony J. Demetris, Michael C. Fishbein, Agnes Fogo, Peter Furness, Ian W. Gibson, Denis Glotz, Pekka Hayry, Lawrence Hunsickern, Michael Kashgarian, Ronald Kerman, Alex J. Magil, Robert MontgomeryKunio Morozumi, Volker Nickeleit, Parmjeet Randhawa, Heinz Regele, Daniel Seron, Surya Seshan, Stale Sund, Kiril Trpkov

Research output: Contribution to journalArticlepeer-review


Antibody-mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent and treat AbAR, enabling excellent outcomes even in patients highly sensitized to the donor prior to transplant. It has become critical to develop standardized criteria for the pathological diagnosis of AbAR. This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001. This classification represents a working formulation, to be revisited as additional data accumulate in this important area of renal transplantation.

Original languageEnglish (US)
Pages (from-to)708-714
Number of pages7
JournalAmerican Journal of Transplantation
Issue number6
StatePublished - Jun 2003


  • Antibody
  • Banff
  • Pathology
  • Rejection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)


Dive into the research topics of 'Antibody-mediated rejection criteria - An addition to the Banff '97 classification of renal allograft rejection'. Together they form a unique fingerprint.

Cite this